Minutes of the Proceedings
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pooled CRISPR-Activation Screening Coupled with Single-Cell RNA-Seq in Mouse Embryonic Stem Cells
ll OPEN ACCESS Protocol Pooled CRISPR-activation screening coupled with single-cell RNA-seq in mouse embryonic stem cells Celia Alda-Catalinas, Melanie A. Eckersley-Maslin, Wolf Reik celia.x.aldacatalinas@gsk. com (C.A.-C.) [email protected]. uk (W.R.) Highlights Protocol for CRISPRa screens with single- cell readout to interrogate gene function Detailed description of CRISPRa screening procedures in mouse embryonic stem cells Detailed steps on how to construct derived single-cell sgRNA amplicon libraries CRISPR/Cas9 screens are a powerful approach to identify key regulators of biological processes. By combining pooled CRISPR/Cas9 screening with a single-cell RNA-sequencing readout, individual perturbations can be assessed in parallel both comprehensively and at scale. Importantly, this allows gene function and regulation to be interrogated at a cellular level in an unbiased manner. Here, we present a protocol to perform pooled CRISPR-activation screens in mouse embryonic stem cells using 103 Genomics scRNA-seq as a readout. Alda-Catalinas et al., STAR Protocols 2, 100426 June 18, 2021 ª 2021 The Authors. https://doi.org/10.1016/ j.xpro.2021.100426 ll OPEN ACCESS Protocol Pooled CRISPR-activation screening coupled with single-cell RNA-seq in mouse embryonic stem cells Celia Alda-Catalinas,1,4,7,* Melanie A. Eckersley-Maslin,1,5,6 and Wolf Reik1,2,3,8,* 1Epigenetics Programme, Babraham Institute, Cambridge CB22 3AT, UK 2Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK 3Centre for Trophoblast Research, University of -
The Oxford – Cambridge Arc Home of the New Innovation Economy
Economic Vision: The Oxford – Cambridge Arc Home of the New Innovation Economy April 2019 Contents 1 Introduction 3 2 The Economic Vision 8 3 The New Innovation Economy: Sectors 11 4 The Innovation & Growth Network 24 5 Achieving Ambitions 29 6 Conclusion: Critical Mass 35 | Introduction 1 Introduction 1.1 This vision’s purpose The purpose of the Economic Vision is to explain the Oxford - Cambridge Arc’s unified proposition as a globally leading innovation and growth catalyst. The Arc offers access to each of the critical ingredients for business and innovation-led growth. This collective offer represents a powerful and coherent expression of the region’s current assets and future potential. This Economic Vision for the Arc sets out an ambition and series of proposals designed to unlock the economic potential of the region and deliver transformative growth for the UK between now and 2050. It provides a vision for how the Arc can better connect its unique and world-leading assets to become truly globally competitive in frontier markets, both for business investment and for top talent. With a bolder brand and stronger international presence the Arc can continue to lead the whole of the UK to the forefront of global innovation excellence in the coming years and decades. 3 | Introduction This Economic Vision is built upon the foundation of This Economic Vision has been developed in the four local industrial strategies which currently partnership with the three LEPs and the Combined demarcate the Arc’s geographic area. These have Authority, who have been given a mandate by Central been prepared by the Oxfordshire (OxLEP), South Government to drive forwards the Economic Vision for East Midlands (SEMLEP) and Buckinghamshire the Arc: Thames Valley (BTVLEP) Local Enterprise Partnerships, as well as the Cambridgeshire & Peterborough Mayoral Combined Authority (CPCA). -
The Proposed Merger of Ealing Hospital NHS Trust and the North West London Hospitals NHS Trust Full Business Case Version 15
The proposed merger of Ealing Hospital NHS Trust and The North West London Hospitals NHS Trust Full Business Case Version 15: 20th June 2014 Table of Contents Table of Contents ................................................................................................ i List of Tables ...................................................................................................... v List of Figures .................................................................................................. vii Abbreviations .................................................................................................. viii 0. Executive Summary ................................................................................... 1 0.1 Background ........................................................................................................ 1 0.2 The case for change ........................................................................................... 1 0.3 London North West Healthcare – What will day 1 feel like? ................................ 2 0.4 London North West Healthcare - What will be different for patients? .................. 3 0.5 Conclusion ......................................................................................................... 3 1. Introduction................................................................................................. 4 1.1 Background to the FINAL business case ............................................................ 4 1.2 Strategic context ................................................................................................ -
PULSE: Speaker Biographies March 2019
PULSE: Speaker Biographies March 2019 Supported by @BIA_UK www.bioindustry.org In order of appearance: Dr Barbara Domayne-Hayman Entrepreneur-in-residence, Francis Crick Institute, CBO, Autifony Therapeutics Ltd and formerly Chairman, Puridify Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech. Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in- residence. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee. Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech. Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School. Steve Bates, OBE CEO, BioIndustry Association Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities. -
Agenda for Change
Incorporating Central Middlesex Hospital Community Services in Brent, Ealing and Harrow Ealing Hospital Northwick Park Hospital St. Mark’s Hospital DIVISION OF INTEGRATED MEDICINE JOB DESCRIPTION CONSULTANT IN RHEUMATOLOGY Page 1 of 26 Contract: Permanent Hours: Full Time Rota: None Intensity category: N/A On-call Availability supplement: N/A Responsible to: Clinical Director, Integrated Medicine Reporting to: Clinical Lead, Rheumatology Principal Location: London North West University Healthcare NHS Trust – Central Middlesex Hospital Tenure: Substantive Page 2 of 26 CONTENTS SUBJECT PAGE 1. Introduction to London North West 4 University Healthcare NHS Trust 2. Trust Management/Trust Board 7 3. Training and Education 8 4. Research 9 5. Healthcare Facilities 10 6. The Application Process 12 7. Particulars of the post and department 13 Appendix A – Job Plan 18 Appendix B – Person Specification 19 Appendix C – Terms and Conditions of Service 21 Page 3 of 26 1. INTRODUCTION THE TRUST London North West University Healthcare NHS Trust London North West University Healthcare NHS Trust is one of the largest integrated care Trusts in the country bringing together hospital and community services across the boroughs of Brent, Harrow and Ealing. Our 9,000 staff, including 1,300 doctors and 4,000 nurses and serves a diverse population of approximately 850,000.The Trust was established in October 2014 following the merger of The North West London Hospitals NHS Trust and Ealing Hospital NHS Trust and has an annual budget of over £640 million. This is a pivotal time for the Trust as we pursue a transformational programme of activity to improve the way healthcare is delivered across the acute and community settings in North West London. -
Medical Research Council Annual Report and Accounts 2006/07 HC 93
06/07 Annual Report and Accounts © Crown Copyright 2006 The text in this document (excluding any Royal Arms and departmental logos) may be reproduced free of charge in any format or medium providing that it is reproduced accurately and not used in a misleading context. The material must be acknowledged as Crown copyright and the title of the document specified. Any queries relating to the copyright in this document should be addressed to The Licensing Division, HMSO, St Clements House, 2-16 Colegate, Norwich, NR3 1BQ. Fax: 01603 723000 or e-mail: licensing@cabinet-office.x.gsi.gov.uk 2 MRC Annual Report and Accounts 2006/07 Medical Research Council Annual Report and Accounts 2006/07 Presented to Parliament by the Secretary of State, and by the Comptroller and Auditor General in pursuance of Schedule I, Sections 2(2) and 3(3) of the Science and Technology Act 1965. Sir John Chisholm Chairman Professor Sir Leszek Borysiewicz Deputy Chairman and Chief Executive Ordered by and printed on London: The Stationery Office 6 February 2008 Price: £18.55 HC 93 The Medical Research Council The MRC RCUK The Medical Research Council (MRC) was set up in 1913 to administer Research Councils UK (RCUK) is a partnership of the seven (formerly public funds for medical research. It was incorporated under its eight) UK Research Councils – public bodies funded mainly by the UK present title by Royal Charter in 1920. A supplemental charter was Government via OSI. granted in 1993 describing the MRC’s new mission following the 1993 government white paper on science and technology. -
Issue 231 • 24 March 2011 Reportersharing Stories of Imperial’S Community News Makers
Issue 231 • 24 March 2011 reporterSharing stories of Imperial’s community News makers Felix Editor Kadhim Shubber on the award-winning newspaper and the 135 students who make it happen > Centre pages plastic steering science from electronics engineering scratch Imperial ranked Professor Why does a in top three Jeff Magee rainforest have for materials on becoming greater capacity science Faculty Principal than a desert? PAGE 3 PAGE 10 PAGE 11 2 >> newsupdate www.imperial.ac.uk/reporter | reporter | 24 March 2011 • Issue 231 Duke of York witnesses healthcare innovations editor’s C orner His Royal Highness The Duke of industry, commerce and health- York (pictured far right) visited care has been central to its mis- Imperial on 2 March to learn about sion since its foundation in 1907. The Duke of York with Lord Ara Darzi and Professor Guang- Big picture the College’s pioneering health- Speaking at the end of his Zhong Yang in the Hamlyn Centre for Robotic Surgery. care innovations in the UK and tour, the Duke said: “Imperial has internationally. He heard about gripped the problem of being able natural disasters are the College’s international partner- to deliver its output internationally for International Trade and Investment, that emotive subjects. Since ships, visited early-stage compa- in a way that many other universi- what you do is utterly brilliant.” the massive earthquake nies in the Imperial Incubator and ties have not been able to achieve. The Duke was also given a tour of the shook Japan on 11 March, learnt about developing robotic It’s not just about education, it’s Incubator which houses 17 early-stage technol- the frightening scenes of technologies to enhance surgery. -
Michael John Owen Wakelam 1955–2020
obituary Michael John Owen Wakelam 1955–2020 We have lost a distinguished biochemist who dedicated his career to the study of phosphatidylinositol signalling in metabolic regulation and to the advancement of lipidomics. ichael John Owen Wakelam passed away on 31 March, 2020 at the Mage of 64, much too early. He became known to colleagues and friends as a scientist highly regarded for his research. He was honoured in 2018 with the Morton Lectureship of the Biochemical Society and was elected a fellow of the Royal Society of Biology. In 2019, he was elected a member of the Academia Europaea. Academic career It was not by chance that Michael turned his focus to phosphatidylinositols (PIs) and lipid signalling. He was a student and later a professor at the University of Birmingham at a time when Britain was the world’s hub of pioneering phospholipid research, such as that by J. N. Hawthorne and Bob Michell on PI in Birmingham. Bob Michell inspired Michael extraordinarily, and they even published a joint review. Subsequently, Michael moved to Cambridge to serve as the director of the Babraham Institute, where Credit: Babraham Institute Rex Dawson and Robin Irvine studied phospholipids, particularly PI metabolism and signalling. A joint publication by Michael and Irvine appeared as well. the Babraham Institute, and he received an the Keystone Symposia on Molecular and Certainly, Michael’s scientific engagement honorary professorship in lipid signalling at Cellular Biology. can be seen in the tradition of these eminent the University of Cambridge Clinical School. phospholipid scientists. In addition, he was an honorary professor Lipid signalling and metabolism Michael’s career path is impressive. -
Creative Zone Central Library Refurbishment Caters for the Digital Generation > Centre Pages
www.imperial.ac.uk reporter issue 196 • 10 October 2008 Creative zone Central Library refurbishment caters for the digital generation > centre pages exhibition ahsc first hidden road redesign birthday corners Imperial Professor Exploring the engineers Stephen Smith Fleming Museum pave the way profile at St Mary’s PAGE 2 PAGE 11 PAGE 13 news update editorial Editor Emily Ross Showcase for bioengineering [email protected] Microscopic devices to detect to communicate with one another. the early onset of infection and In addition, Peter Vincent, a joint On Monday morning 4,900 new faces research into a highly developed PhD student from the Departments appeared across our campuses, part of the brain were some of of Bioengineering and Aeronautics, bubbling with excitement and anticipation at the start of the latest advances discussed at discussed his work on how their Imperial experience. And, as staff and students look an international symposium last lipoproteins are transported into month (18–19 September). artery walls and what this could forward to a new academic year, the College reflects on a The Bioengineering 08 sympo- contribute ultimately to the onset of triumphant 12 months since the creation of the UK’s first sium brought together more than heart disease. Academic Health Science Centre, and the innovation and 190 scientists creativity that the unique partnership between Imperial from around the and the NHS has already inspired. On pages 10 and 11 read world. Hosted about the journey of the AHSC’s development through the by the College’s Department of eyes of Professor Stephen Smith, Principal of the Faculty of Bioengineering, the Medicine and CEO of the Imperial College Healthcare NHS event focused on Trust, and hear about the moment he realised the AHSC was setting the agenda going to become a reality. -
24, 2021 Program Book Table of Contents
June 21 – 24, 2021 Program Book Table of Contents Genetics Society of America . 3 Conference Organizers . 5 International C. elegans Board 2021 . 7 Sponsors . 9 Schedule of Events . 11 General Information . 16 Conference App . .. 17 Oral Presenters . 17 Poster Presenters . 17 Viewing Oral Sessions . 18 Attending Live Poster Sessions . .. 18 Live Poster Session Schedule . 19 Sponsor and Exhibitor Education Sessions . 21 Daily Meet-ups via Zoom and Remo . 22 Viewing Virtual Posters on the App . 23 Slack Chat Channels . 23 Job Postings . 23 Presenting Author Index . 23 Conference Policies . 24 Exhibits . 27 Oral Presentation and Workshop Session Listings . 29 Poster Session Listings . 58 23rd International C. elegans Conference | 2 Genetics Society of America Genetics Society of America GSA is an international scientific society representing more than 5,000 researchers and educators around the world. As well as connecting researchers through conferences and career programs, we publish two peer- edited scholarly journals, GENETICS and G3: Genes|Genomes|Genetics. We encourage you to join GSA so you can make use of exclusive member benefits and get involved in the Society’s many programs, including professional development training, awards, advocacy, and more. Join us as we work to advance the field and serve our community. Visit genetics-gsa.org for more information. GENETICS has been innovating since 1916, publishing high quality original research across the breadth of the field. G3: Genes|Genomes|Genetics is an open access journal that publishes high quality, useful results regardless of perceived impact. 2021 GSA Board of Directors Officers Directors Journal Editors Hugo Bellen, President Swathi Arur Brenda J. -
Crp-Brochure-080518-Na-Web.Pdf
Where Life Meets Science Where Life Meets Science “Research excellence is one of the The Park offers a flexible and fostering CHESTERFORD RESEARCH PARK Building on 60 years of continuous R&D at Chesterford is being developed as a 250 Foreword defining features of the Cambridge environment for both established R&D PROVIDES A SUPERBLY FLEXIBLE Chesterford, innovative biotechnology and acre low density scheme. To date, more landscape. Both academically and in companies and start-ups alike, providing AND FUTURE PROOFED pharmaceutical occupiers thrive in than 300,000 sq ft of laboratory and R&D the transfer of knowledge through to cutting-edge research facilities within a state-of-the-art accommodation and enjoy space has been let and occupied. Further ENVIRONMENT FOR BOTH EARLY commercial application, our region has community that encourages collaboration modern, central facilities, all set within a phases of construction are proposed to STAGE AND ESTABLISHED R&D established an international reputation at every stage. Chesterford Research Park unique and idyllic parkland location. extend the development to approximately that attracts outstanding academics, will help ensure that Cambridge ideas COMPANIES 1 million sq ft. researchers and business leaders who continue to change the world.” collectively drive discovery in so many different spheres. The depth and amazing Professor Sir Leszek Borysiewicz diversity of that research capability is Vice-Chancellor of the University of Cambridge. apparent at Chesterford Research Park. (Retired 2017) -
Trends and Challenges in Computational RNA Biology Alina Selega and Guido Sanguinetti*
Selega and Sanguinetti Genome Biology (2016) 17:253 DOI 10.1186/s13059-016-1117-7 MEETINGREPORT Open Access Trends and challenges in computational RNA biology Alina Selega and Guido Sanguinetti* Abstract complemented by two lively poster sessions, where partic- ipants had an opportunity to engage with over 40 posters A report on the Wellcome Trust Conference on during evening drinks receptions. Computational RNA Biology, held in Hinxton, UK, on In this report, we briefly recount the content of the 17–19 October 2016. conference by providing condensed, headline-style sum- Keywords: RNA, Review, Computational biology maries of the research described in the talks and some posters. Within the scope of this brief report, we cannot possibly do justice to the wealth and breadth of material Introduction presented and we will not be able to mention much inter- Recent years have witnessed a profound shift in our esting research, particularly within the poster sessions. understanding of RNA biology. Several novel biochemical We would like to stress that omissions in this report are and sequencing techniques are producing vast amounts not based on quality, but simply on a personal judgement of data that fundamentally challenge the textbook view as to what material could be most coherently presented in of RNA as a simple intermediate step of gene expression, a very limited space. revealing a wealth of unexpected new roles and shed- ding light on the complexity of the RNA world. While Transcripts the emerging picture unequivocally points to the cen- Perhaps the most remarkable discovery in modern RNA trality of RNA as a mediator of most cellular functions, biology is the realization of the diversity of the transcrip- the richness and heterogeneity of modern datasets pose tome.